Beyond the World Health Organization grading of infiltrating gliomas: Advances in the molecular genetics of glioma classification

Annals of Translational Medicine

Volumn 3, Issue 7, 2015, Pages

  Vigneswaran, Krishanthan ^a   Neill, Stewart ^a   Hadjipanayis, Costas G ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Biological markers; Genomics; Glioma; Mutations; Prognosis

Indexed keywords

EID: 85015461489     PISSN: 23055839     EISSN: 23055847     Source Type: Journal    
DOI: 10.3978/j.issn.2305-5839.2015.03.57     Document Type: Review

References (57)

1. Hirose Y, Sasaki H, Abe M, et al. Subgrouping of gliomas on the basis of genetic profiles. Brain Tumor Pathol 2013;30:203-8.
2. Kim YW, Koul D, Kim SH, et al. Identification of prognostic gene signatures of glioblastoma: a study based on TCGA data analysis. Neuro Oncol 2013;15:829-39.
3. Olar A, Aldape KD. Biomarkers classification and therapeutic decision-making for malignant gliomas. Curr Treat Options Oncol 2012;13:417-36.
4. Olar A, Aldape KD. Using the molecular classification of glioblastoma to inform personalized treatment. J Pathol 2014;232:165-77.
5. Sulman EP, Guerrero M, Aldape K. Beyond grade: molecular pathology of malignant gliomas. Semin Radiat Oncol 2009;19:142-9.
6. Theeler BJ, Yung WK, Fuller GN, et al. Moving toward molecular classification of diffuse gliomas in adults. Neurology 2012;79:1917-26.
7. Erridge SC, Hart MG, Kerr GR, et al. Trends in classification, referral and treatment and the effect on outcome of patients with glioma: a 20 year cohort. J Neurooncol 2011;104:789-800.
8. Pollo B. Neuropathological diagnosis of brain tumours. Neurol Sci 2011;32 Suppl 2:S209-11.
9. Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007;114:97-109.
10. Appin CL, Brat DJ. Molecular genetics of gliomas. Cancer J 2014;20:66-72.
11. Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009;360:765-73.
12. Kurian KM, Haynes HR, Crosby C, et al. IDH mutation analysis in gliomas as a diagnostic and prognostic biomarker. Br J Neurosurg 2013;27:442-5.
13. Huse JT, Wallace M, Aldape KD, et al. Where are we now? And where are we going? A report from the Accelerate Brain Cancer Cure (ABC2) low-grade glioma research workshop. Neuro Oncol 2014;16:173-8.
14. Suzuki A, Nobusawa S, Natsume A, et al. Olig2 labeling index is correlated with histological and molecular classifications in low-grade diffuse gliomas. J Neurooncol 2014;120:283-91.
15. Lin N, Yan W, Gao K, et al. Prevalence and clinicopathologic characteristics of the molecular subtypes in malignant glioma: a multi-institutional analysis of 941 cases. PLoS One 2014;9:e94871.
16. Zou P, Xu H, Chen P, et al. IDH1/IDH2 mutations define the prognosis and molecular profiles of patients with gliomas: a meta-analysis. PLoS One 2013;8:e68782.
17. Kloosterhof NK, Bralten LB, Dubbink HJ, et al. Isocitrate dehydrogenase-1 mutations: a fundamentally new understanding of diffuse glioma? Lancet Oncol 2011;12:83-91.
18. Thompson CB. Metabolic enzymes as oncogenes or tumor suppressors. N Engl J Med 2009;360:813-5.
19. Agarwal S, Sharma MC, Jha P, et al. Comparative study of IDH1 mutations in gliomas by immunohistochemistry and DNA sequencing. Neuro Oncol 2013;15:718-26.
20. Boots-Sprenger SH, Sijben A, Rijntjes J, et al. Significance of complete 1p/19q co-deletion, IDH1 mutation and MGMT promoter methylation in gliomas: use with caution. Mod Pathol 2013;26:922-9.
21. Weller M, Pfister SM, Wick W, et al. Molecular neuro-oncology in clinical practice: a new horizon. Lancet Oncol 2013;14:e370-9.
22. Jiang H, Ren X, Cui X, et al. 1p/19q codeletion and IDH1/2 mutation identified a subtype of anaplastic oligoastrocytomas with prognosis as favorable as anaplastic oligodendrogliomas. Neuro Oncol 2013;15:775-82.
23. Masui K, Cloughesy TF, Mischel PS. Review: molecular pathology in adult high-grade gliomas: from molecular diagnostics to target therapies. Neuropathol Appl Neurobiol 2012;38:271-91.
24. Leu S, von Felten S, Frank S, et al. IDH/MGMT-driven molecular classification of low-grade glioma is a strong predictor for long-term survival. Neuro Oncol 2013;15:469-79.
25. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005;352:997-1003.
26. Bady P, Sciuscio D, Diserens AC, et al. MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status. Acta Neuropathol 2012;124:547-60.
27. Weller M, Stupp R, Reifenberger G, et al. MGMT promoter methylation in malignant gliomas: ready for personalized medicine? Nat Rev Neurol 2010;6:39-51.
28. Wick W, Weller M, van den Bent M, et al. MGMT testing-the challenges for biomarker-based glioma treatment. Nat Rev Neurol 2014;10:372-85.
29. Sahebjam S, McNamara MG, Mason WP. Emerging biomarkers in anaplastic oligodendroglioma: implications for clinical investigation and patient management. CNS Oncol 2013;2:351-8.
30. Kalinina J, Peng J, Ritchie JC, et al. Proteomics of gliomas: initial biomarker discovery and evolution of technology. Neuro Oncol 2011;13:926-42.
31. Van Meir EG, Hadjipanayis CG, Norden AD, et al. Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. CA Cancer J Clin 2010;60:166-93.
32. Ostrom QT, Gittleman H, Farah P, et al. CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2006-2010. Neuro Oncol. 2013;15 Suppl 2:ii1-56.
33. Ostrom QT, Gittleman H, Liao P. CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2007-2011, Neuro Oncol 2014;16 suppl 4:iv1-63.
34. El-Hateer H, Souhami L, Roberge D, et al. Low-grade oligodendroglioma: an indolent but incurable disease? Clinical article. J Neurosurg 2009;111:265-71.
35. Paulus W. GFAP, Ki67 and IDH1: perhaps the golden triad of glioma immunohistochemistry. Acta Neuropathol 2009;118:603-4.
36. Yaziji H, Massarani-Wafai R, Gujrati M, et al. Role of p53 immunohistochemistry in differentiating reactive gliosis from malignant astrocytic lesions. Am J Surg Pathol 1996;20:1086-90.
37. Myung JK, Cho HJ, Park CK, et al. IDH1 mutation of gliomas with long-term survival analysis. Oncol Rep 2012;28:1639-44.
38. Jiao Y, Killela PJ, Reitman ZJ, et al. Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas. Oncotarget 2012;3:709-22.
39. Sahm F, Reuss D, Koelsche C, et al. Farewell to oligoastrocytoma: in situ molecular genetics favor classification as either oligodendroglioma or astrocytoma. Acta Neuropathol 2014;128:551-9.
40. Cairncross G, Jenkins R. Gliomas with 1p/19q codeletion: a.k.a. oligodendroglioma. Cancer J 2008;14:352-7.
41. Jiang HH, Ren XH, Zhang Z, et al. A molecular classification system for anaplastic glioma. Zhonghua Wai Ke Za Zhi 2013;51:1104-9.
42. Guan X, Vengoechea J, Zheng S, et al. Molecular subtypes of glioblastoma are relevant to lower grade glioma. PLoS One 2014;9:e91216.
43. Neill SG, Fisher KE. Section III: Molecular diagnostics in neuro-oncology. Curr Probl Cancer 2014;38:175-9.
44. Gupta K, Salunke P. Molecular markers of glioma: an update on recent progress and perspectives. J Cancer Res Clin Oncol 2012;138:1971-81.
45. Zhang C, Bao Z, Zhang W, et al. Progress on molecular biomarkers and classification of malignant gliomas. Front Med 2013;7:150-6.
46. Le Mercier M, Hastir D, Moles Lopez X, et al. A simplified approach for the molecular classification of glioblastomas. PLoS One 2012;7:e45475.
47. Nicolaidis S. Personalized medicine in neurosurgery. Metabolism 2013;62 Suppl 1:S45-8.
48. Aldave G, Tejada S, Pay E, et al. Prognostic value of residual fluorescent tissue in glioblastoma patients after gross total resection in 5-aminolevulinic Acid-guided surgery. Neurosurgery 2013;72:915-20; discussion 920-1.
49. Hofer S, Rushing E, Preusser M, et al. Molecular biology of high-grade gliomas: what should the clinician know? Chin J Cancer 2014;33:4-7.
50. Phillips HS, Kharbanda S, Chen R, et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 2006;9:157-73.
51. Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010;17:98-110.
52. Noushmehr H, Weisenberger DJ, Diefes K, et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 2010;17:510-22.
53. Singh D, Chan JM, Zoppoli P, et al. Transforming fusions of FGFR and TACC genes in human glioblastoma. Science 2012;337:1231-5.
54. Ajaz M, Jefferies S, Brazil L, et al. Current and investigational drug strategies for glioblastoma. Clin Oncol (R Coll Radiol) 2014;26:419-30.
55. Simon M, Hosen I, Gousias K, et al. TERT promoter mutations: a novel independent prognostic factor in primary glioblastomas. Neuro Oncol 2015;17:45-52.
56. Labussière M, Boisselier B, Mokhtari K, et al. Combined analysis of TERT, EGFR, and IDH status defines distinct prognostic glioblastoma classes. Neurology 2014;83:1200-6.
57. Malkki H. Neuro-oncology: TERT promoter mutations could indicate poor prognosis in glioblastoma. Nat Rev Neurol 2014;10:546.